Find your next paid study

Merck Sharp & Dohme LLCNCT07058077

Heterozygous or Homozygous Familial Hypercholesterolemia

An Open-label, Single Arm, Multicenter Extension Study to Evaluate Long-term Safety and Tolerability of Inclisiran in Participants With Heterozygous or Homozygous Familial Hypercholesterolemia Who Have Completed the Pediatric ORION-16, ORION-13, ORION-20 or ORION-19 Studies (VICTORION-PEDS-OLE)

The purpose of this open-label, single arm, multicenter extension study is to evaluate the long-term safety and tolerability of inclisiran in participants with…

Novartis PharmaceuticalsNCT05682378

Phase 1

A Phase 1 Open-label, Multicenter, First-in-human, Ascending Dose Trial Evaluating the Safety and Tolerability of a Lipid Nanoparticle Formulation of CRISPR-Guide RNA-Cas9 Nuclease (CTX310) for In Vivo Editing of the Angiopoietin-like 3 (ANGPTL3) Gene in Participants With Refractory Dyslipidemias

This is a single-arm, open-label, multicenter, ascending dose Phase 1 trial that will enroll participants 18 to 75 years of age with dyslipidemias that are ref…

CardiovascularMetabolic DiseaseDyslipidemias+7 more

CRISPR Therapeutics AGNCT07491172

Observational

A Cluster Randomized Controlled Trial To Evaluate The Efficacy Of Cascade Testing In Identifying At-risk Family Members Of Individuals With Familial Hypercholesterolemia (FH) In PCP

The purpose of this study is to evaluate the effectiveness of two models of cascade testing in identifying at-risk family members of individuals diagnosed with…

Familial Hypercholesterolemia

Heterozygous Familial HypercholesterolemiaPremature Coronary Heart Disease

~$10 – $6,250

Mayo ClinicNCT07653555

Phase 1

Open-label, Phase 1b, Single Ascending Dose Study to Evaluate the Safety of VERVE-102 Administered to Patients With Heterozygous Familial Hypercholesterolemia or Premature Coronary Artery Disease Who Require Additional Lowering of Low-density Lipoprotein Cholesterol

VT-10201 is an Open-label, Phase 1b, Single-ascending Dose Study That Will Evaluate the Safety of VERVE-102 Administered to Patients With Heterozygous Familial…

Verve Therapeutics, Inc.NCT06164730

Phase 2

2-Hydroxybenzylamine (2-HOBA) to Reduce HDL Modification and Improve HDL Function in Familial Hypercholesterolemia (FH)

The Investigators will test the hypothesis that 2-HOBA will reduce modification of HDL and LDL and improve HDL function in humans with heterozygous FH. The Inv…

Familial Hypercholesterolemia

Vanderbilt University Medical CenterNCT04941599

~$10 – $6,250

Familial Hypercholesterolemia - Homozygous

Two Part (Double-blind Inclisiran Versus Placebo [Year 1] Followed by Open-label Inclisiran [Year 2]) Randomized Multicenter Study to Evaluate Safety, Tolerability, and Efficacy of Inclisiran in Children (2 to Less Than 12 Years) With Homozygous Familial Hypercholesterolemia and Elevated LDL-cholesterol

This is a pivotal phase III study designed to evaluate safety, tolerability, and efficacy of inclisiran in children (aged 2 to \<12 years) with homozygous fami…

Novartis PharmaceuticalsNCT06597006

Familial Hypercholesterolemia - Heterozygous

Two Part (Double-blind Inclisiran Versus Placebo [Year 1] Followed by Open-label Inclisiran [Year 2]) Randomized Multicenter Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children (6 to Less Than 12 Years) With Heterozygous Familial Hypercholesterolemia and Elevated LDL- Cholesterol

This is a pivotal phase III study designed to evaluate safety, tolerability, and efficacy of inclisiran in children (aged 6 to \<12 years) with heterozygous fa…

Novartis PharmaceuticalsNCT06597019

HoFH, the International Clinical Collaborators - A Global HoFH Data-sharing Platform

Homozygous familial hypercholesterolemia (HoFH), a rare inherited disorder caused by bi-allelic mutations in the LDL Receptor pathway, is characterized by extr…

Homozygous Familial Hypercholesterolemia

University of PennsylvaniaNCT04815005

~$10 – $750

Observational

Comparing Direct and Indirect Methods for Cascade Screening in Familial Hypercholesterolemia (FH) and Long QT Syndrome (LQTS)

An important aspect of successful genomic medicine implementation is developing effective approaches for screening at-risk family members after probands are id…

Long QT SyndromeFamilial HypercholesterolemiaEthics+1 more

University of Maryland, BaltimoreNCT05348564

~$10 – $6,250

LOWER: Lomitapide Observational Worldwide Evaluation Registry

This global product exposure registry is a multicentre, long-term, prospective, observational cohort study (exposure registry), designed to evaluate the long t…

Homozygous Familial Hypercholesterolemia

~$10 – $1,050

Amryt PharmaNCT02135705

Familial Hypercholesterolemia - Heterozygous

Randomized, Placebo-Controlled, Double-Blind, Phase 3b Study to Evaluate the Efficacy and Safety of Lerodalcibep in Children and Adolescents, 6 to 17 Years of Age, With Heterozygous Familial Hypercholesterolemia on Stable Diet and Oral Lipid-Lowering Therapy

The goal of this clinical trial is to assess the LDL-Cholesterol reductions at Week 12 and Week 24 with monthly dosing of lerodalcibep (Lerochol) 300 mg admini…